Serum resistin predicts aortic stiffness in coronary artery disease
Serum concentrations of resistin is a biomarker for aortic stiffness in patients with coronary artery disease (CAD), a recent study from Taiwan has shown.
The aortic stiffness of 104 CAD patients (mean age 65.63±9.17 years; 75 percent male) was measured using carotid-femoral pulse wave velocity. Those with acute myocardial infarction, pulmonary oedema, acute infections or were taking calcium, bisphosphonates or oestrogens were excluded.
Fasting blood samples were collected from the participants and were subjected to laboratory tests to measure levels of blood urea nitrogen (BUN), high- and low-density lipoprotein (HDL, LDL) and high-sensitivity C-reactive protein (hs-CRP).
Of the participants, 35.6 percent (n=37) had high aortic stiffness. Diabetes mellitus was more common in patients with high aortic stiffness (p=0.001).
Serum resistin levels were significantly higher in patients with both CAD and diabetes mellitus than in those without the diabetes comorbidity (p=0.003). Resistin levels were not significantly different with respect to the presence of the hypertension comorbidity.
Multivariate forward stepwise linear regression analysis showed that diabetes mellitus (β, 0.239; p=0.006), waist circumference (β, 0.384; p<0.001) and age (β, 0.203; p=0.019) were all significant predictors of resistin concentrations in CAD patients.
Subsequent multivariate logistic regression showed that higher serum resistin (odds ratio [OR], 1.275; 95 percent CI, 1.065 to 1.527; p=0.008), diabetes mellitus (OR, 4.906; 1.418 to 16.970; p=0.012), older age (OR, 1.089; 1.005 to 1.180; p=0.036) and higher hs-CRP (OR, 1.226; 1.010 to 1.486; p=0.039) were independent predictors of aortic stiffness in CAD patients.